Aarkstore Enterprise: 2015

Friday, October 23, 2015

Aarkstore - Evolution of Technologies for Therapeutic Antibodies-From mAbs to Biosimilars

Scope of report

The scope of the report is to highlight and gauge existing technologies in the production of therapeutic mAbs. The report also discusses key insights on interchangeability and substitution of therapeutic antibodies and biosimilars.
Further, there is also an assessment of the current drivers and restraints that affect the uptake of biosimilars.

The report answers key questions that are paramount for understanding the technologies involved in the production of therapeutic antibodies, such as:

• What are the various types of monoclonal therapeutic antibodies?
• Why is there a need for alternate forms of therapeutic antibodies?
• What is the likely future direction for research in the development and manufacture of monoclonal antibodies?
• What are the key features of a genetically modified mouse for antibody production?
• How do ethical concerns drive the direction of research of future monoclonal antibodies?
• What are the crucial features in establishing biosimilarity?
• Is interchangeability between innovator monoclonal antibodies and biosimilars ever achievable?
• What are the limitations in the technologies used to evaluate the extents of biosimilarity?
• Who are the potential players in biosimilar manufacture and what stage of product pipeline is their focus on?
• What are the current biosimilars under development as an alternative for major mAbs?
• What is the existing balance between drivers and restraints in the uptake of biosimilars?

Main benefits / Why should you buy this report?

The idea of using antibodies for therapy is about a century old. The successful production of antibodies has always been stalled by challenges like immunogenicity, scaling to industry level production, microheterogenity, regulatory approvals and pricing. This report will help stakeholders to understand prevailing technologies and their merits and limitations. It discusses:
• Technological deterrents encountered so far and the successful strategies to neutralize these
• The contemporary situation and forthcoming prospects of existing technologies
• The stages of the product pipeline that enterprises are centring on for success
• Ethical and regulatory considerations that set the path for the future

You can order full Report @

http://www.aarkstore.com/biotechnology/117430/evolution-of-technologies-for-therapeutic-antibodiesfrom-mabs-to-biosimilars

Contact Details:

Aarkstore Enterprise

Phone: +91 998 729 5242 / +91 - 22 2756 4953
Email: enquiry@aarkstore.com
Our Website: http://www.aarkstore.com
Our Blog : http://www.aarkstore.com/blog/
Our News Section : http://www.aarkstore.com/news

Aarkstore - Healthcare Market Access: Morocco

The report provides in-depth information on:

o Country Landscape – The section details about the geographical details of Morocco. It also details the prevalent economic conditions of Morocco in terms of GDP per capita, GDP sources, demographic profile of the country, and political structure and environment.

o Healthcare infrastructure – The section provides data on the current health and hygiene status of the citizens based parameters such as: sanitation and safe drinking water access, HIV/AIDS prevalence, contraceptive usage, maternal and infant mortality, hospital bed and physician density etc. The sections also give detailed account of general healthcare structure of the country in terms of primary, secondary and tertiary care, and also a general note on the country’s health expenditure.

o Pharmaceutical Market Access: The sections gives detailed account of various types of health insurance currently operating in Morocco, their coverage in terms of health risks and benefits and also in terms of population coverage. The section gives detailed account of health insurance for public sector and private sector employees. The section also compares the efficiencies of various African medical regulatory agencies and their approval approach for a MNC pharmaceutical company. More specifically, the section deals with the regulatory agency and the new drug and reimbursement approval in Morocco.

Key questions answered in this report:

The report answers majority of key questions that are paramount for the success of a pharmaceutical company such as:
• Economic status of the country: GDP, GDP per capita, growth rate, major sources of GDP, income distribution
• Demographic structure of the country: age wise distribution of population, growth rate of population, educational level of population
• Healthcare infrastructure and status of the country: access to safe drinking and sanitary facilities reflecting the social hygiene, maternal and infant mortality rates reflecting the satus of healthcare scenario, expenditure eon healthcare, hospital bed and physician density reflecting the healthcare infrastructure of the state
• Healthcare system of the country: in terms of private and public healthcare infrastructure, primary, secondary and tertiary healthcare setups.
• Health insurance system in the country: Different forms of health insurance system and their governing bodies, the coverage of health insurance for public and private employees, penetration of health insurance etc.
• New drug approval process and reimbursement approval process

Key benefits / Why should you buy this report:

As every country’s market access landscape is unique and evolving, it makes a prudent decision to have a country specific market access strategy. Moreover, the success of any pharmaceutical company hinges on successfully navigating challenges posed by the various stakeholders and regulatory bodies for effective product commercialization.

This report will serve as a handy tool for pharmaceutical and other related healthcare stakeholders to:

• Understand the macro and micro parameters that will play a pivotal role in making business decisions
• Identify, target and collaborate with the relevant stakeholders that hold key to effective product commercialization
• Conceptualize and formulate plausible market access strategies based on the insights generated
• Identify and foresee the major trends and policies likely to impact the regulatory, pricing and reimbursement landscape of the country
• Capitalize on the opportunities presented by the country’s pharmaceutical market and mitigate the challenges posed by the competitors and stakeholders/regulatory bodies
• Generate market specific insights that are actionable and commercially viable
• Leverage market access insights by incorporating physicians and payer priorities so as to develop effective sales and marketing strategies resulting in increased brand and company revenue
• Correctly ascertain the appropriate market access levers and barriers that will drive or hamper the brand performance
• Prioritize and assign optimal resources required for implementation of various market access activities

You can order full Report @

http://www.aarkstore.com/pharmaceuticals-healthcare/117429/healthcare-market-access-morocco

Contact Details:

Aarkstore Enterprise

Aarkstore - Healthcare Market Access: Egypt

The report provides in-depth information on:

o Country Landscape – This section covers information on the prevailing economic environment in the country and the reform efforts being taken. The GDP growth has improved indicating trends in the economic indicators and improvement. The demographic profile of the country indicates that a majority of the population is young

o Healthcare infrastructure – Insightful review of the country’s healthcare system and health status with key health indicators are presented in this section. Moreover, healthcare expenditure and major healthcare providers are mentioned. The profiles of major hospitals and the number of healthcare personnel in the country are also covered.

o Overview of Pharmaceutical Market – This section depicts the pharmaceutical market in terms of size, growth, product mix and key players operating in the country. A special emphasis has been laid on the key drivers and barriers impacting the pharmaceutical market of the country. Furthermore, major diseases with high burden for the country have been covered.

o Market Access: This section dwells on the role and importance of various stakeholders in product commercialization process and gatekeepers holding the key to the access for pharmaceutical products. Various regulatory aspects crucial for approval and marketing of various categories of pharmaceutical products have been captured. In addition, analysis of pricing and reimbursement landscape along with the prescribing policies are covered.

Key questions answered in this report:

The report answers majority of key questions that are paramount for the success of a pharmaceutical company such as:

• How stable is the country’s political climate, major economic indices like GDP size and growth, rate of inflation, FDI, etc. impacting the level of business sentiments
• How lucrative is the pharmaceutical market of the country in terms of size, growth, product portfolio mix, key market segments and the level of competitive intensity
• Who are the relevant stakeholders that needs to be engaged effectively for successful product commercialization
• What are the key trends and policies that may impact the future market access landscape and how to effectively counter them
• Which are the cost-containment measures that have been adopted by the country’s government and may be introduced in the near future
• Which are the major disease segments that a pharmaceutical company can focus for product launch and growth based on the disease burden in the country
• What are the key policies that impacts the pricing and reimbursement decisions in both public and private sector
• Whether the country’s pharmaceutical market represents a compelling commercial case to invest and offers significant opportunities that can be successfully tapped resulting in significant revenue generation

Key benefits / Why should you buy this report:

As every country’s market access landscape is unique and evolving, it makes a prudent decision to have a country specific market access strategy. Moreover, the success of any pharmaceutical company hinges on successfully navigating challenges posed by the various stakeholders and regulatory bodies for effective product commercialization.

This report will serve as a handy tool for pharmaceutical and other related healthcare stakeholders to:

• Understand the macro and micro parameters that will play a pivotal role in making business decisions
• Identify, target and collaborate with the relevant stakeholders that hold key to effective product commercialization
• Conceptualize and formulate plausible market access strategies based on the insights generated
• Identify and foresee the major trends and policies likely to impact the regulatory, pricing and reimbursement landscape of the country
• Capitalize on the opportunities presented by the country’s pharmaceutical market and mitigate the challenges posed by the competitors and stakeholders/regulatory bodies
• Generate market specific insights that are actionable and commercially viable
• Leverage market access insights by incorporating physicians and payer priorities so as to develop effective sales and marketing strategies resulting in increased brand and company revenue
• Correctly ascertain the appropriate market access levers and barriers that will drive or hamper the brand performance
• Prioritize and assign optimal resources required for implementation of various market access activities

You can order full Report @

http://www.aarkstore.com/pharmaceuticals-healthcare/117428/healthcare-market-access-egypt

Contact Details:

Aarkstore Enterprise

Aarkstore - Healthcare Market Access: Thailand

The report provides in-depth information on:

o Country Landscape – This section covers information on the prevailing economic environment in the country. The GDP per capita has improved indicating trends in the economic indicators and improvement. The demographic profile of the country indicates that a majority of the population is in the economically productive age group.

o Healthcare infrastructure – Insightful review of the country’s healthcare system and health status with key health indicators are presented in this section. Moreover, healthcare expenditure and major healthcare providers are mentioned. The profiles of major hospitals and the number of healthcare personnel in the country are also covered.

o Overview of Pharmaceutical Market – This section depicts the pharmaceutical market in terms of size, growth, product mix and key players operating in the country. A special emphasis has been laid on the key drivers and barriers impacting the pharmaceutical market of the country. Furthermore, major diseases with high burden for the country have been covered.

o Market Access: This section dwells on the role and importance of various stakeholders in product commercialization process and gatekeepers holding the key to the access for pharmaceutical products. Various regulatory aspects crucial for approval and marketing of various categories of pharmaceutical products have been captured. In addition, analysis of pricing and reimbursement landscape along with the prescribing policies are covered.

Key questions answered in this report:

The report answers majority of key questions that are paramount for the success of a pharmaceutical company such as:

• How stable is the country’s political climate, major economic indices like GDP size and growth, rate of inflation, FDI, etc. impacting the level of business sentiments
• How lucrative is the pharmaceutical market of the country in terms of size, growth, product portfolio mix, key market segments and the level of competitive intensity
• Who are the relevant stakeholders that needs to be engaged effectively for successful product commercialization
• What are the key trends and policies that may impact the future market access landscape and how to effectively counter them
• Which are the cost-containment measures that have been adopted by the country’s government and may be introduced in the near future
• Which are the major disease segments that a pharmaceutical company can focus for product launch and growth based on the disease burden in the country
• What are the key policies that impacts the pricing and reimbursement decisions in both public and private sector
• Whether the country’s pharmaceutical market represents a compelling commercial case to invest and offers significant opportunities that can be successfully tapped resulting in significant revenue generation

Key benefits / Why should you buy this report:

As every country’s market access landscape is unique and evolving, it makes a prudent decision to have a country specific market access strategy. Moreover, the success of any pharmaceutical company hinges on successfully navigating challenges posed by the various stakeholders and regulatory bodies for effective product commercialization.

This report will serve as a handy tool for pharmaceutical and other related healthcare stakeholders to:

• Understand the macro and micro parameters that will play a pivotal role in making business decisions
• Identify, target and collaborate with the relevant stakeholders that hold key to effective product commercialization
• Conceptualize and formulate plausible market access strategies based on the insights generated
• Identify and foresee the major trends and policies likely to impact the regulatory, pricing and reimbursement landscape of the country
• Capitalize on the opportunities presented by the country’s pharmaceutical market and mitigate the challenges posed by the competitors and stakeholders/regulatory bodies
• Generate market specific insights that are actionable and commercially viable
• Leverage market access insights by incorporating physicians and payer priorities so as to develop effective sales and marketing strategies resulting in increased brand and company revenue
• Correctly ascertain the appropriate market access levers and barriers that will drive or hamper the brand performance
• Prioritize and assign optimal resources required for implementation of various market access activities

You can order full Report @

http://www.aarkstore.com/pharmaceuticals-healthcare/117427/healthcare-market-access-thailand

Contact Details:

Aarkstore Enterprise

Tuesday, October 20, 2015

Aarkstore - Healthcare Market Access: Vietnam

The report provides in-depth information on:

o Country Landscape – This section covers information on the prevailing economic environment in the country and dwells on both macro and micro economic indicators. The demographic profile of the country highlights the growing importance of middle class and increasing access to internet. It also captures the political landscape along with the opportunities and challenges presented by the country.

o Healthcare infrastructure – Insightful review of the country’s healthcare system and health status with key health indicators are presented in this section. Moreover, healthcare expenditure and share of public and private sectors are prominently discussed in the section. The profiles of major hospitals and the number of healthcare personnel in the country are also comprehensively covered.

o Overview of Pharmaceutical Market – This section depicts the pharmaceutical market in terms of size, growth, product mix and key players operating in the country. A special emphasis has been laid on the key drivers and barriers impacting the pharmaceutical market of the country. Furthermore, the profiles of major diseases with high burden for the country have been covered.

o Market Access: This section dwells on the role and importance of various stakeholders in product commercialization process and gatekeepers holding the key to the access for pharmaceutical products. Various regulatory aspects crucial for approval and marketing of various categories of pharmaceutical products have been captured comprehensively. In addition, detailed analysis of pricing and reimbursement landscape along with the prescribing policies and influence, price build-up and trends and various drug lists impacting reimbursement is covered.

Data-rich tables and figures have been used generously to augment the report and assist the reader in better understanding of the subject matter.

Key questions answered in this report:

The report answers majority of key questions that are paramount for the success of a pharmaceutical company such as:

• How stable is the country’s political climate, major economic indices like GDP size and growth, rate of inflation, FDI, etc. impacting the level of business sentiments
• How lucrative is the pharmaceutical market of the country in terms of size, growth, product portfolio mix, key market segments and the level of competitive intensity
• Who are the relevant stakeholders that needs to be engaged effectively for successful product commercialization
• What are the key factors that influence the physician prescribing habits and payer/hospital formulary decisions
• What are the key trends and policies that may impact the future market access landscape and how to effectively counter them
• Which are the cost-containment measures that have been adopted by the country’s government and may be introduced in the near future
• Which are the major disease segments that a pharmaceutical company can focus for product launch and growth based on the disease burden in the country
• What are the key policies that impacts the pricing and reimbursement decisions in both public and private sector
• Whether the country’s pharmaceutical market represents a compelling commercial case to invest and offers significant opportunities that can be successfully tapped resulting in significant revenue generation

Key benefits / Why should you buy this report:

As every country’s market access landscape is unique and evolving, it makes a prudent decision to have a country specific market access strategy. Moreover, the success of any pharmaceutical company hinges on successfully navigating challenges posed by the various stakeholders and regulatory bodies for effective product commercialization.

This report will serve as a handy tool for pharmaceutical and other related healthcare stakeholders to:

• Understand the macro and micro parameters that will play a pivotal role in making business decisions
• Identify, segment, target and collaborate with the relevant stakeholders that hold key to effective product commercialization
• Conceptualize and formulate plausible market access strategies based on the insights generated
• Identify and foresee the major trends and policies likely to impact the regulatory, pricing and reimbursement landscape of the country
• Capitalize on the opportunities presented by the country’s pharmaceutical market and mitigate the challenges posed by the competitors and stakeholders/regulatory bodies
• Generate market specific insights that are actionable and commercially viable
• Leverage market access insights by incorporating physicians and payer priorities so as to develop effective sales and marketing strategies resulting in increased brand and company revenue
• Correctly ascertain the appropriate market access levers and barriers that will drive or hamper the brand performance
• Prioritize and assign optimal resources required for implementation of various market access activities

You can order full Report @

http://www.aarkstore.com/pharmaceuticals-healthcare/117424/healthcare-market-access-vietnam

Contact Details:

Aarkstore Enterprise

Aarkstore - Healthcare Market Access: Poland

The report provides in-depth information on:

o Country Landscape – This section covers information on the prevailing economic environment in the country and the reform efforts being taken. The GDP growth has improved indicating trends in the economic indicators and improvement. The demographic profile of the country indicates a negative population growth rate

o Healthcare infrastructure – Insightful review of the country’s healthcare system and health status with key health indicators are presented in this section. Moreover, healthcare expenditure and major healthcare providers are mentioned. The profiles of major hospitals and the number of healthcare personnel in the country are also covered.

o Overview of Pharmaceutical Market – This section depicts the pharmaceutical market in terms of size, growth, product mix and key players operating in the country. A special emphasis has been laid on the key drivers and barriers impacting the pharmaceutical market of the country. Furthermore, major diseases with high burden for the country have been covered.

o Market Access: This section dwells on the role and importance of various stakeholders in product commercialization process and gatekeepers holding the key to the access for pharmaceutical products. Various regulatory aspects crucial for approval and marketing of various categories of pharmaceutical products have been captured. In addition, analysis of pricing and reimbursement landscape along with the prescribing policies are covered.

Key questions answered in this report:

The report answers majority of key questions that are paramount for the success of a pharmaceutical company such as:

• How stable is the country’s political climate, major economic indices like GDP size and growth, rate of inflation, FDI, etc. impacting the level of business sentiments
• How lucrative is the pharmaceutical market of the country in terms of size, growth, product portfolio mix, key market segments and the level of competitive intensity
• Who are the relevant stakeholders that needs to be engaged effectively for successful product commercialization
• What are the key trends and policies that may impact the future market access landscape and how to effectively counter them
• Which are the cost-containment measures that have been adopted by the country’s government and may be introduced in the near future
• Which are the major disease segments that a pharmaceutical company can focus for product launch and growth based on the disease burden in the country
• What are the key policies that impacts the pricing and reimbursement decisions in both public and private sector
• Whether the country’s pharmaceutical market represents a compelling commercial case to invest and offers significant opportunities that can be successfully tapped resulting in significant revenue generation

Key benefits / Why should you buy this report:

As every country’s market access landscape is unique and evolving, it makes a prudent decision to have a country specific market access strategy. Moreover, the success of any pharmaceutical company hinges on successfully navigating challenges posed by the various stakeholders and regulatory bodies for effective product commercialization.

This report will serve as a handy tool for pharmaceutical and other related healthcare stakeholders to:

• Understand the macro and micro parameters that will play a pivotal role in making business decisions
• Identify, target and collaborate with the relevant stakeholders that hold key to effective product commercialization
• Conceptualize and formulate plausible market access strategies based on the insights generated
• Identify and foresee the major trends and policies likely to impact the regulatory, pricing and reimbursement landscape of the country
• Capitalize on the opportunities presented by the country’s pharmaceutical market and mitigate the challenges posed by the competitors and stakeholders/regulatory bodies
• Generate market specific insights that are actionable and commercially viable
• Leverage market access insights by incorporating physicians and payer priorities so as to develop effective sales and marketing strategies resulting in increased brand and company revenue
• Correctly ascertain the appropriate market access levers and barriers that will drive or hamper the brand performance
• Prioritize and assign optimal resources required for implementation of various market access activities

You can order full Report @

http://www.aarkstore.com/pharmaceuticals-healthcare/117425/healthcare-market-access-poland

Contact Details:

Aarkstore Enterprise

Aarkstore - Healthcare Market Access: Indonesia

The report provides in-depth information on:

o Country Landscape This section covers information on the prevailing economic environment in the country and dwells on both macro and micro economic indicators. The demographic profile of the country highlights the growing importance of middle class and increasing access to internet. It also captures the political landscape along with the opportunities and challenges presented by the country.

o Healthcare infrastructure Insightful review of the countrys healthcare system and health status with key health indicators are presented in this section. Moreover, healthcare expenditure and share of public and private sectors are prominently discussed in the section. The profiles of major hospitals and the number of healthcare personnel in the country are also comprehensively covered

o Overview of Pharmaceutical Market This section depicts the pharmaceutical market in terms of size, growth, product mix and key players operating in the country. A special emphasis has been laid on the key drivers and barriers impacting the pharmaceutical market of the country. Furthermore, the profiles of major diseases with high burden for the country have been covered

o Market Access: This section dwells on the role and importance of various stakeholders in product commercialization process and gatekeepers holding the key to the access for pharmaceutical products. Various regulatory aspects crucial for approval and marketing of various categories of pharmaceutical products have been captured comprehensively. In addition, detailed analysis of pricing and reimbursement landscape along with the prescribing policies and influence, price build-up and trends and various drug lists impacting reimbursement is covere

Data-rich tables and figures have been used generously to augment the report and assist the reader in better understanding of the subject matter

Key questions answered in this report:

The report answers majority of key questions that are paramount for the success of a pharmaceutical company such as:

How stable is the countrys political climate, major economic indices like GDP size and growth, rate of inflation, FDI, etc. impacting the level of business sentiments

How lucrative is the pharmaceutical market of the country in terms of size, growth, product portfolio mix, key market segments and the level of competitive intensity

Who are the relevant stakeholders that needs to be engaged effectively for successful product commercialization

What are the key factors that influence the physician prescribing habits and payer/hospital formulary decisions

What are the key trends and policies that may impact the future market access landscape and how to effectively counter them

Which are the cost-containment measures that have been adopted by the countrys government and may be introduced in the near future

Which are the major disease segments that a pharmaceutical company can focus for product launch and growth based on the disease burden in the country

What are the key policies that impacts the pricing and reimbursement decisions in both public and private sector

Whether the countrys pharmaceutical market represents a compelling commercial case to invest and offers significant opportunities that can be successfully tapped resulting in significant revenue generation

Key benefits / Why should you buy this report:

As every countrys market access landscape is unique and evolving, it makes a prudent decision to have a country specific market access strategy. Moreover, the success of any pharmaceutical company hinges on successfully navigating challenges posed by the various stakeholders and regulatory bodies for effective product commercialization.

This report will serve as a handy tool for pharmaceutical and other related healthcare stakeholders to

Understand the macro and micro parameters that will play a pivotal role in making business decisions

Identify, segment, target and collaborate with the relevant stakeholders that hold key to effective product commercialization

Conceptualize and formulate plausible market access strategies based on the insights generated

Identify and foresee the major trends and policies likely to impact the regulatory, pricing and reimbursement landscape of the country

Capitalize on the opportunities presented by the countrys pharmaceutical market and mitigate the challenges posed by the competitors and stakeholders/regulatory bodies

Generate market specific insights that are actionable and commercially viable

Leverage market access insights by incorporating physicians and payer priorities so as to develop effective sales and marketing strategies resulting in increased brand and company revenue

Correctly ascertain the appropriate market access levers and barriers that will drive or hamper the brand performance

Prioritize and assign optimal resources required for implementation of various market access activities

You can order full Report @

http://www.aarkstore.com/pharmaceuticals-healthcare/117423/healthcare-market-access-indonesia

Contact Details:

Aarkstore Enterprise

Aarkstore - Healthcare Market Access: Czech Republic

The report provides in-depth information on:

o Country Landscape – This section covers information on the prevailing economic environment in the country. The GDP per capita has improved indicating trends in the economic indicators and improvement. The demographic profile of the country indicates that a majority of the population is in the economically productive age group.

o Healthcare infrastructure – Insightful review of the country’s healthcare system and health status with key health indicators are presented in this section. Moreover, healthcare expenditure and major healthcare providers are mentioned. The profiles of major hospitals and the number of healthcare personnel in the country are also covered.

o Overview of Pharmaceutical Market – This section depicts the pharmaceutical market in terms of size, growth, product mix and key players operating in the country. A special emphasis has been laid on the key drivers and barriers impacting the pharmaceutical market of the country. Furthermore, major diseases with high burden for the country have been covered.

o Market Access: This section dwells on the role and importance of various stakeholders in product commercialization process and gatekeepers holding the key to the access for pharmaceutical products. Various regulatory aspects crucial for approval and marketing of various categories of pharmaceutical products have been captured. In addition, analysis of pricing and reimbursement landscape along with the prescribing policies are covered.

Key questions answered in this report:

The report answers majority of key questions that are paramount for the success of a pharmaceutical company such as:

• How stable is the country’s political climate, major economic indices like GDP size and growth, rate of inflation, FDI, etc. impacting the level of business sentiments
• How lucrative is the pharmaceutical market of the country in terms of size, growth, product portfolio mix, key market segments and the level of competitive intensity
• Who are the relevant stakeholders that needs to be engaged effectively for successful product commercialization
• What are the key trends and policies that may impact the future market access landscape and how to effectively counter them
• Which are the cost-containment measures that have been adopted by the country’s government and may be introduced in the near future
• Which are the major disease segments that a pharmaceutical company can focus for product launch and growth based on the disease burden in the country
• What are the key policies that impacts the pricing and reimbursement decisions in both public and private sector
• Whether the country’s pharmaceutical market represents a compelling commercial case to invest and offers significant opportunities that can be successfully tapped resulting in significant revenue generation

Key benefits / Why should you buy this report:

As every country’s market access landscape is unique and evolving, it makes a prudent decision to have a country specific market access strategy. Moreover, the success of any pharmaceutical company hinges on successfully navigating challenges posed by the various stakeholders and regulatory bodies for effective product commercialization.

This report will serve as a handy tool for pharmaceutical and other related healthcare stakeholders to:

• Understand the macro and micro parameters that will play a pivotal role in making business decisions
• Identify, target and collaborate with the relevant stakeholders that hold key to effective product commercialization
• Conceptualize and formulate plausible market access strategies based on the insights generated
• Identify and foresee the major trends and policies likely to impact the regulatory, pricing and reimbursement landscape of the country
• Capitalize on the opportunities presented by the country’s pharmaceutical market and mitigate the challenges posed by the competitors and stakeholders/regulatory bodies
• Generate market specific insights that are actionable and commercially viable
• Leverage market access insights by incorporating physicians and payer priorities so as to develop effective sales and marketing strategies resulting in increased brand and company revenue
• Correctly ascertain the appropriate market access levers and barriers that will drive or hamper the brand performance
• Prioritize and assign optimal resources required for implementation of various market access activities

You can order full Report @

http://www.aarkstore.com/pharmaceuticals-healthcare/117426/healthcare-market-access-czech-republic

Contact Details:

Aarkstore Enterprise

Friday, October 16, 2015

Aarkstore - 4G/LTE Network deployments worldwide

This report provides you with comprehensive source of 4G/LTE network deployments, both planned and in service. Together with this report you receive ONE YEAR access to the current version of the report plus remote consultant support limited to 30minutes.

Some of companies mentioned:

AMC (Albanian Mobile Communications )
Eagle Mobile
Vodafone Albania
Andorra Telecom
Movicel
Claro
Movistar (Telefonica)
Nextel
Personal (Telecom Argentina)
Armentel (Beeline)
Orange Armenia
VivaCell (MTS)
Energy Australia
NBN Co
NetComm Wireless
Optus
Telstra
vividwireless
Vodafone Hutchison Australia
3 Austria
A1 Telecom (Telekom Austria)
ONE (Orange)
T-Mobile
Azercell
Azerfon
Bakcell
BTC - The Bahamas Telecommunications Company
Batelco
menaTelecom
Viva Bahrain (STC)
Zain
GrameenPhone
Orascom Bangladesh
Robi Axiata Bangladesh
Teletalk
Warid Bangladesh (Airtel )
Lime Barbados
Dialog (CDMA)
MTS Belarus
Velcom
Yota Bel (Scartel)
BASE (KPN Belgium)
Mobistar (France Telekom)
Proximus (Belgacom Mobile)
BTL
Cell One
Bhutan Telecom ( B-Mobile)
Tashi Infocomm
Entel Movil
BH Telecom
Mobilne Sprske (mtel)
Mascom Wireless
Algar Telecom
Claro
Oi
SKY Brasil
Vivo (Telefonica )
DSTCom
GloBul (Cosmo Bulgaria Mobile)
M-Tel (Mobiltel Bulgaria )
Vivacom (BTC/Vivatel)
Alltech Telecom
Cadcomms
CamGSM/Cellcard (MobiTel)
Mfone (CamShin)

Nokia Siemens Networks
Ericsson
Huawei
Samsung
Cisco
ZTE
Alcate-Lucent
Alvarion
NEC

You can order full Report @

http://www.aarkstore.com/telecommunications/152206/4glte-network-deployments-worldwide

Contact Details:

Aarkstore Enterprise

Aarkstore - 4G Telecom Conferences Worldwide

This report “4G Telecom Conferences Worldwide”provides you with comprehensive list of the main events in area of 2G/3G/4G Wireless Systems in 2012 & 2013.

Companies Mentioned

Smith Micro Software, Broadcom, Cambium Networks, Intel, Motorola Solutions, CSIRO, Chungwa Telecom, Mentum, Tektronix Communications, Aspider, Effortel, Ericsson, HUAWEI, intucell, Spider Cloud Wireless, T-Mobile, Nokia Siemens Networks, Alcatel-Lucent, Orange, Bravo Tech Inc. (BTI), Ablaze Wireless, Telecom Italia, Qualcomm, Tellabs, Gemalto, Arieso

Table Of Content

Types of Events:

Conferences
Summits
Workshops
Seminars

The data are grouped in the following way:

Conference Name
Type of event
Country
Start Date
End Date
Venue
Organizer
Main Sponsors
Website

You can order full Report @

http://www.aarkstore.com/telecommunications/152205/4g-telecom-conferences-worldwide

Contact Details:

Aarkstore Enterprise

Thursday, October 15, 2015

Aarkstore - Touch Panel Report

Description

The report covers the global touch panel market, focusing on the key market trends and purchasing considerations rather than on technology details. Forecasts are for 2014-2020, with the full year 2014 data not being available at the time of writing, although quarterly figures up to 3Q14 were used to inform the 2014 forecast where available. Historical data is provided back to at least 2010 where relevant.

Executive Summary

The Global Touch Screen Technology Market has so far been characterised by extreme fragm entation both in technology and in supply chain. Ten years of double-digit growth in both units and revenues, combined with relatively low barriers to entry, have encouraged a huge number of suppliers. At the same time there has been no ‘one-size-fits-all’ technology solution, with several different technology approaches meeting the needs of different categories of device or usage scenario. However, since 2009, one approach (PCAP) has captured the highest-volume touch categories of mobile phones and tablets.

You can order full Report @

http://www.aarkstore.com/technology/148667/touch-panel-report

Contact Details:

Aarkstore Enterprise

Aarkstore - Aliphatic Solvents in Asia

Description

The report covers the characteristics of the market for aliphatic solvents in Asia and the Middle East including trends, characteristics, country splits, segmentations and analysis of end uses.

The report covers aliphatic solvents and hydrocarbon solvent mixtures that are further segmented into paraffinic, Paraffinic solvents, Varnish makers and paints (VM&P) naphtha, Mineral spirits, Stoddard solvent, Solvent 140. Segments of the market covered in the report include mineral spirits, hexanes, heptanes, naphthas and other solvents. End uses mentioned in the report include paints and coatings, printing inks, pharmaceuticals, adhesives, rubber & polymer, agricultural chemicals, other uses.

Some Key Findings of the Report

• The global solvents (oxygenated, hydrocarbon, and halogenated) market was estimated to be about 25 MT in volume in 2014. Aliphatic hydrocarbon solvents constitute 27% of the total solvents market.

• The historical growth (2010-2013) of the global / Asia-Pacific / Middle East aliphatic hydrocarbon solvents market is primarily attributed to a single factor i.e. growth in demand for solvents from the end-user industries as a result of economic growth, particularly in emerging markets.

• Shale gas discovery and exploitation have led to light naphtha becoming an over-supplied raw material in the aliphatic hydrocarbon solvents market, leading to lower the raw material costs for manufacturers of aliphatic hydrocarbon solvents.

• Solvents are highly regulated chemical substances as solvents emit high levels of VOCs in the atmosphere. Many global- as well as regional-level regulatory compliance rules/norms have been formulated to minimize the VOC emissions and to ensure compliance.

• VM&P naphtha constitutes around 80% of the aliphatic solvents market owing to its usage across range or end-user industries.

• Since the 1960’s, solvents have typically been used across a range of industries such as paints and coatings, printing inks and cleaning agents; they are also used in the pharmaceutical and synthetic rubber industries. The largest end-user customer segment to date is the paints and coatings industry.

• Corresponding to the growth of the printing inks industry, the demand for solvents as core ingredients (solvents account for ~ 50% to 70% of overall weight of printing inks too) is also expected to grow leading to profitable opportunities for market players.

• There is a rising trend is taking place of development of ‘solvent-free’ pharmaceuticals production processes (such as use of ball mills for molecule size reduction and dissolution) and the replacement/substitution of existing solvents.

• The Asia-Pacific aliphatic hydrocarbon solvents market is fragmented with only a small number of organized players having a presence across the entire region. Companies such as Shell Chemicals, ExxonMobil Chemicals, and two others together account for approximately 20% of the Asia-Pacific aliphatic solvents market.

• China will remain a ‘net importer’ for many ‘specialized solvents/product lines’, while relying on production and domestic consumption of commonly used aliphatic hydrocarbon solvents.

• Saudi Arabia and UAE produce nominal quantities of ‘specialized’ aliphatic hydrocarbon solvents for domestic consumption; they export the generic solvents and also raw material in bulk to other countries.

You can order full Report @

http://www.aarkstore.com/chemicals/139115/aliphatic-solvents-in-asia

Contact Details:

Aarkstore Enterprise

Aarkstore - Natural Gas Supply Outlook

Description

This report deals with the supply chain for natural gas, from the production stage, through processing and transportation, to distribution and consumption by industrial and retail customers.
It describes and explains how supply works and its key features in the European, US and Chinese markets.

It then looks at the future for natural gas, under a range of future scenarios covering then next ten years, including an optimistic scenario where increased economic activity has driven up the price of energy, a ‘base’ scenario of activity remaining at recent levels and a negative scenario of low economic activity and energy prices. In each case it looks at the likely structure of natural gas supply in the different regions.

US

Shale gas will account for nearly half of total US gas production by 2040. Production volumes will continue to grow because of increased drilling efficiencies and more shale gas fields coming on stream.
The increased production is expected to decrease the country’s dependence on imports from Canada. LNG exports from the US are expected to increase beginning 2016.
Use of natural gas in sectors other than electrical power production is expected to expand in the medium term. The fertilizer and chemical sector industries particularly are expected to start new projects driving long term demand.

Europe

Europe is likely to see declining local production and increasing imports from areas such as West Africa the US, Canada and North Africa, resulting in more LNG supply. Thus two thirds of Europe’s natural gas needs are expected to be met by imports by the year 2025. With local production volumes expected to decline, and issues over the security of Russian gas, LNG imports are projected to approximately double between 2014 and 2020.

Due to the rise in investments in infrastructure, in particular new pipeline projects and the increased use of LNG, gas prices in Europe are likely to increase up to 2020. Prices are expected to stabilise beyond 2020.
Increases in natural gas consumption in Europe will be driven mainly by demand from the residential-commercial and industrial sectors from southern Europe and Turkey in 2015-25.

China

China’s National Energy Administration (NEA) set the 2020 production target of shale gas at 30 billion cubic meters (1 trillion cubic feet), however TBRC believes much of China’s unconventional gas reserves may prove difficult or impossible to exploit during this time frame.

By 2020, pipelines from Central Asia, Myanmar, Russia and imported liquefied natural gas mainly from Qatar and Australia are expected to play a major role in supplying a large part of China’s gas.
As China tries to wean itself from its use of cheap coal gas is likely to play a larger part in the energy consumption mix. The Chinese government expects to increase natural gas’s share of total energy consumption to around 8% by the end of 2015 and to 10% by 2020. BP plc predicts that China’s natural gas consumption will rise 270% by 2035.

You can order full Report @

http://www.aarkstore.com/energy-power/139116/natural-gas-supply-outlook

Contact Details:

Aarkstore Enterprise

Tuesday, October 13, 2015

Aarkstore - Power Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018

WinterGreen Research announces that it has a new study on power wheelchairs. The 2012 study has 467 pages, 143 tables and figures. Worldwide markets are poised to achieve remarkable growth as the populations age all over the world, as technology and manufacturing efficiency bring down the unit costs, and as older people are more affluent and can afford better power wheelchairs.

According to Susan Eustis, lead author of the study, "Reimbursement drives power wheelchair markets." As people and governments pay for medical insurance more money is available for medical treatment and equipment.

The government provides people over age 65 with medical insurance in the US. In many parts of the developed world, there is complete medical coverage provided by the government, though working people tend to supplement government coverage with medical insurance. Power wheelchair users may be eligible to receive a power chair at little to no cost. Vendors research the qualifications and negotiate the payments for many potential power wheelchair users.

As the population ages, people are more frail and need assistance for mobility. Hospital and homecare wheelchair technology is evolving to give people with disabilities more mobility. Mobility depends on a wheelchair that is fit to purpose. Are people going to move themselves? Are they going to be inside or outside? Is the wheelchair used for traveling by car? Many issues impact the choice of a wheelchair, including cost and reimbursement availability.

Power wheelchair markets are poised to create the ability for people to get more exercise and impact the healthcare delivery industry. By encouraging mobility of people who were previously bed ridden, the quality of life rises significantly. Wheelchairs impact care delivery, permitting the patient to control mobility for the rehabilitation efforts. Power wheel chairs give patients the ability to control movement.

Transport power wheelchairs are used for permitting patients to go from home by auto to another place. Patients and family gain more control over care delivery with the availability of rehabilitation and travel with power transport wheelchairs. Care can be delivered in familiar settings.

Power wheelchair markets at $1.1 billion in 2011 are anticipated to reach $3.9 billion in 2018. Market growth comes in large part from demand for mobility from people who might otherwise be bedridden.

WinterGreen Research is an independent research organization funded by the sale of market research studies all over the world and by the implementation of ROI models that are used to calculate the total cost of ownership of equipment, services, and software. The company has 35 distributors worldwide, including Global Information Info Shop, Market Research.com, Research and Markets, Bloomberg, and Thompson Financial.

You can order full Report @

http://www.aarkstore.com/energy-power/100845/power-wheelchair-market-shares-strategies-forecasts-worldwide

Contact Details:

Aarkstore Enterprise

Aarkstore - Russian Market of Artificial Lung Ventilation Devices in 2013-2014

The global market of artificial lung ventilation (ALV) devices is characterized by steady incremental growth. The compound annual growth rate (CAGR) of the global ALV devices market for the 2006-2013 period was 4.0%, which is somewhat under than the average figure for the medical device market as a whole, 5.0%. The global ALV devices market is expected to grow by 4.4% a year on average towards USD 1333 mln. in 2020.

The Russian market of ALV devices grew quickly in the 2009-2012 period. Regional health care modernization programs of 2011-2013 significantly broadened the field to RUB 6.8 bln. in 2012. This was 1.7 times the 2011 market size. With the regional programs over by the middle of 2013, demand in 2013-2014 shifted from new devices to expendables and support of existing unit pools. In fact, the level of consumption that would normally have been reached in 2014-2015 was achieved in 2012, the year most ALV units were obtained on program money. As a result, in 2013 the Russian market of new ALV units fell by more than 40% to 2011 levels. It continued to decline in the 1st half of 2014.

Public procurement dominates the Russian market. Private buyers in 2013 only had a 10-16% presence, in the first half of 2014 about 20-25% because of the retreat of public clients.

REPORT SCOPE

The report provides full information about the Russian ALV devices market in 2013 the 1st half of 2014 and general background information on the global ALV devices market. It also contains a forecast of the Russian ALV devices market development till 2018.

REPORT INCLUDES THE FOLLOWING PARTS:

STUDY METHODOLOGY section includes a list of information resources, which were used while preparing the report. It also contains description of ALV devices under study.

INTRODUCTION section clarifies the structure of the report. Attention is drawn to the absence of one generally accepted classification of ALV devices. MDpros own classification of ALV devices is given.

The first part of the report (RUSSIAN MEDICAL DEVICE MARKET IN 2013-2018) encompasses the most important characteristics of the Russian medical device market. It contains information about its dynamics and structure, public procurement and import-export operations. The most important Russian medical device market trends and significant factors, determining its current state, are outlined. This part also includes a forecast of the Russian medical device market development until 2018. Based on the analysis of drivers and barriers for the market growth, two possible scenarios of market development are presented.

The second part (THE GLOBAL AND RUSSIAN MARKETS OF ALV DEVICES IN 2011-2014) provides information about the dynamics and structure of the global respiratory care devices market and ALV devices market as its subsegment. It also includes data on the main market players and the biggest M&A deals between companies operating on the global ALV devices market. Finally, key characteristics of Russian ALV devices market are outlined.

The third part (SALES OF ALV DEVICES BY MANUFACTURER) includes a list of the worlds largest manufacturers of ALV devices in the following breakdown: Manufacturer Trademarks of ALV devices Images of ALV devices). MDpros classification of ALV devices, presented on the Russian public procurement market, is provided. Additionally, this section contains data on sales of different ALV devices manufacturers operating in Russia.

The fourth part (IMPORTS AND EXPORTS OF ALV DEVICES) encompasses data on import-export operations of ALV devices. Import information includes annual and quarterly dynamics of imports, the structure of imports by manufacturing countries and companies. Besides, Top-20 recipients of imported ALV devices at customs are named. Finally, it includes a list of the largest recipients of ALV devices by leading manufacturers at customs. Export information contains annual dynamics of ALV devices exports and information about industry leaders.

The fifth part (PUBLIC PROCUREMENT OF ALV DEVICES) is dedicated to the results of ALV devices public procurement analysis. It includes data on the dynamics and structure of public procurement of ALV devices and the most important trends in this area. The largest purchasers of ALV devices in monetary and physical terms are presented. A list of public healthcare institutions, which purchased the most expensive ALV devices, is shown. It also contains a list of the biggest suppliers of ALV devices under government contracts in monetary and physical terms. Moreover, this section provides information about Russian regions, which are the leaders in ALV devices public procurement purchasing.

The sixth part (ALV DEVICES SALES REVIEW) is a price review of ALV devices purchased under government contracts. The dynamics of prices of different ALV devices (incl. federal district breakdown) and average prices are shown. Besides, minimum, maximum and weighted average prices of Top-15 ALV devices purchased under government contracts are provided.

The seventh part (A FORECAST OF THE RUSSIAN MARKET OF ALV DEVICES TO 2018) dedicated to an overlook of the future perspectives of Russian ALV market. Based on the analysis of drivers and barriers for the market growth, two scenarios for market development are presented.

The eighth part (REFERENCE: ALV DEVICE USAGE AND APPLICATION STATISTICS) is designed to provide information about essential aspects of ALV devices circulation in Russia: Russian medical devices legislation, fields of application, indications for use, ALV devices equipment hospital standards, etc.

The ninth part (BUSINESS ENVIRONMENT IN RUSSIA) provides a practical guide to what is necessary for achieving compliance with Russias regulatory requirements. It also describes Russian policies on health care system and medical device market development.

SOURCES OF INFORMATION

THE PUBLIC PROCUREMENT OF MEDICAL DEVICES DATABASE:
MDpros database on public (government and municipal) procurement of medical devices and expendables for medical facilities. Updated every month using information from www.zakupki.gov.ru, processed for details and broken down by segment of the medical device market.

THE EXPORTS AND IMPORTS DATABASE:
MDpros database of customs transactions for medical devices and expendables. Updated every month using official statistics from customs, processed for details and broken down by segment of the medical device market.

OPEN SOURCES:
Official health care statistics
Publications of international marketing agencies
News

You can order full Report @

http://www.aarkstore.com/medical-devices/131556/russian-market-of-artificial-lung-ventilation-devices

Contact Details:

Aarkstore Enterprise

Friday, October 9, 2015

Overlook China Acetoacetanilide Export Overlook 2014

Overlook China Acetoacetanilide Export Overlook 2014 provides detailed analysis to identify the target commodities from customs records. The analysis service give a full view of commodities export trade records, provides comprehensive data regarding target products export by month, exporters, destinations, export price, export volume, etc. This analysis service give a full view of target products export trade trend, helping you make more informed decisions.

Benefits and features

- Identify target commodity from the HS code-based and commodities-mixed Customs raw data.
- Find top markets for the products your company exports.
- Track your competitors export transactions - see their volume, price and countries of trade.
- Find new sources for the products or raw materials your company buys.
- Find new customers for your transportation and logistics services.
- Monitor your contractual agreements with overseas suppliers
- More.

Who need this analysis?

- Producer of Acetoacetanilide
- Traders of Acetoacetanilide
- Buyers of Acetoacetanilide
- Raw material suppliers of Acetoacetanilide
- Intermediate suppliers of Acetoacetanilide
- More

1 Summary of Chinas export of Acetoacetanilide in 2014
2 Summary of China Acetoacetanilide export by ports in 2014
3 Summary of China Acetoacetanilide export by mode of trade in 2014
4 Summary of China Acetoacetanilide export by corporate property in 2014
5 Summary of China Acetoacetanilide export by mode of transport in 2014
6 Summary of China Acetoacetanilide export by month in 2014
7 Summary of China Acetoacetanilide export by exporters in 2014
8 Summary of China Acetoacetanilide export by destinations in 2014
9 Case study-XX Company
9-1 XX Companys Acetoacetanilide export by month
9-2 XX Companys Acetoacetanilide export by destinations

You can order full Report @

http://www.aarkstore.com/agrochemical/136760/overlook-china-acetoacetanilide-export-overlook

Thursday, May 21, 2015

Aarkstore - Lonsurf (Colorectal Cancer) - Forecast and Market Analysis to 2023

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, “Lonsurf (Colorectal Cancer) - Forecast and Market Analysis to 2023”. Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Erbitux and Vectibix are not recommended.

Taiho Pharmaceutical’s Lonsurf (TAS-102) is an oral nucleoside antitumor drug which launched in 2014 for the treatment of chemotherapy-refractive metastatic CRC in Japan. In May 2014, Taiho Pharmaceutical announced that the Phase III RECOURSE trial met its primary outcome of OS and that the company is preparing for regulatory submission in the US and Europe. In October 2014, Taiho announced that Lonsurf has received FDA Fast-Track designation and had initiated rolling NDA submission. This positive outcome follows the announcement in March 2014 that Lonsurf had gained regulatory approval for the treatment of recurrent unresectable locally advanced or metastatic CRC in Japan based on Phase II data.

Scope

- Overview of Colorectal Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Lonsurf including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Lonsurf for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Colorectal Cancer
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Lonsurf performance
- Obtain sales forecast for Lonsurf from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and China)

Order full Report with TOC and Sample page visit:

http://www.aarkstore.com/healthcare/87979/lonsurf-colorectal-cancer-forecast-and-market-analysis-to-2023

Related Market Research reports: Healthcare Market Research Reports

About Aarkstore Enterprise

Aarkstore Enterprise is a leading provider of business and financial information and solutions worldwide. We specialize in providing online market business information on market research reports, books, magazines, conference at competitive prices, and strive to provide excellent and innovative service to our customers.

Contact Details:

Aarkstore Enterprise
Phone: +91 9987295242 / 022-27564953
Email: enquiry@aarkstore.com
Our Website: http://www.aarkstore.com
Our Blog : http://www.aarkstore.com/blog/
Latest News : http://www.aarkstore.com/news
Facebook: https://www.facebook.com/aarkstoredotcom

Aarkstore - Dengue Global Clinical Trials Review, H1, 2013

Summary

GlobalDatas clinical trial report, “Dengue Global Clinical Trials Review, H1, 2013" provides data on the Dengue clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Dengue. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Dengue. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Order full Report with TOC and Sample page visit:

http://www.aarkstore.com/pharmaceuticals-healthcare/118380/dengue-global-clinical-trials-review-h1-2013

Related Market Research reports: Healthcare Market Research Reports

About Aarkstore Enterprise

Contact Details: